CD79A and COVID-19: In a setting with a medium level of COVID‐19 incidence (621 cases per million per day), an antibody response of 20%–40% BA.1 IgA binding antibodies is needed to achieve at least 80% protection against infection for an average of 155–225 days within our study cohort.